Advertisement

PharmacoEconomics

, Volume 30, Issue 8, pp 647–660 | Cite as

Economic Evaluations of Childhood Influenza Vaccination

A Critical Review
  • Anthony T. NewallEmail author
  • Mark Jit
  • Philippe Beutels
Review Article

Abstract

The potential benefits of influenza vaccination programmes targeted at children have gained increasing attention in recent years.

We conducted a literature search of economic evaluations of influenza vaccination in those aged ≤18 years. The search revealed 20 relevant articles, which were reviewed. The studies differed widely in terms of the costs and benefits that were included. The conclusions were generally favourable for vaccination, but often applied a wider perspective (i.e. including productivity losses) than the reference case for economic evaluations used in many countries. Several evaluations estimated outcomes from a single-year epidemiological study, which may limit their validity given the year-to-year variation in influenza transmissibility, virulence, vaccine match and prior immunity. Only one study used a dynamic transmission model able to fully incorporate the indirect herd protection to the wider community.

The use of dynamic models offers great scope to capture the population-wide implications of seasonal vaccination efforts, particularly those targeted at children.

Keywords

Influenza Economic Evaluation Influenza Vaccine Influenza Vaccination Health Technology Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

ATN holds a National Health and Medical Research Council (NHMRC) Training Fellowship (no. 630724; Australian-based Public Health Fellowship). PB is supported by ‘SIMID’ (Simulation Models of Infectious Disease Transmission and Control Processes), a project funded by the Flemish Government Agency for Innovation by Science and Technology (IWT).

ATN has in the past received research funding for other previous projects from a manufacturer of the influenza vaccine, GlaxoSmithKline Pty Ltd. MJ and PB have no conflicts to declare.

ATN led the project and conducted the literature review. PB initiated the idea for the review. ATN and MJ assembled the tables in consultation with PB. All authors contributed to the study design, the analysis and interpretation of the literature, and the drafting of the manuscript. ATN acts as the guarantor for the content of this paper.

This paper is part of a theme issue co-edited by Lisa Prosser, University of Michigan, USA, and no external funding was used to support the publication of this theme issue.

References

  1. 1.
    Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58 (RR-8): 1–52PubMedGoogle Scholar
  2. 2.
    Centers for Disease Control and Prevention. Seasonal influenza vaccination coverage among children aged 6 months-18 years: eight immunization information system sentinel sites, United States, 2009–10 influenza season. MMWR Morb Mortal Wkly Rep 2010; 59(39): 1266–9Google Scholar
  3. 3.
    Mereckiene J, Cotter S, Nicoll A, et al. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill 2008; 13(43): 19017PubMedGoogle Scholar
  4. 4.
    UK Department of Health. JCVI statement on seasonal influenza vaccination of 30 December 2010 [online]. Available from URL: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_123209.pdf [Accessed 2012 Jun 13]
  5. 5.
    Monto AS, Koopman JS, Longini Jr IM. Tecumseh study of illness: XIII. Influenza infection and disease, 1976–1981. Am J Epidemiol 1985; 121(6): 811–22Google Scholar
  6. 6.
    Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5(3): e74PubMedCrossRefGoogle Scholar
  7. 7.
    Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21(4): 273–83PubMedCrossRefGoogle Scholar
  8. 8.
    Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005; 353(24): 2559–67PubMedCrossRefGoogle Scholar
  9. 9.
    Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292(11): 1333–40PubMedCrossRefGoogle Scholar
  10. 10.
    Newall AT, Scuffham PA. Influenza-related disease: the cost to the Australian healthcare system. Vaccine 2008; 26(52): 6818–23PubMedCrossRefGoogle Scholar
  11. 11.
    Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009; 3(1): 37–49PubMedCrossRefGoogle Scholar
  12. 12.
    Savidan E, Chevat C, Marsh G. Economic evidence of influenza vaccination in children. Health Policy 2008; 86(2–3): 142–52PubMedCrossRefGoogle Scholar
  13. 13.
    Glezen WP. Herd protection against influenza. J Clin Virol 2006; 37(4): 237–43PubMedCrossRefGoogle Scholar
  14. 14.
    Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010; 303(10): 943–50PubMedCrossRefGoogle Scholar
  15. 15.
    Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344(12): 889–96PubMedCrossRefGoogle Scholar
  16. 16.
    Kelly H, Newall AT. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008; 8(8): 462–3PubMedCrossRefGoogle Scholar
  17. 17.
    Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7(10): 658–66PubMedCrossRefGoogle Scholar
  18. 18.
    Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7: CD001269PubMedGoogle Scholar
  19. 19.
    Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356(7): 685–96PubMedCrossRefGoogle Scholar
  20. 20.
    Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5(2): 67–75PubMedCrossRefGoogle Scholar
  21. 21.
    Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25(10): 870–9PubMedCrossRefGoogle Scholar
  22. 22.
    Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25(10): 860–9PubMedCrossRefGoogle Scholar
  23. 23.
    Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009; 22(3): 244–9PubMedCrossRefGoogle Scholar
  24. 24.
    European Medicines Agency. Fluenz influenza vaccine (live attenuated, nasal) [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001101/WC500103712.pdf [Accessed 2012 Jun 13]
  25. 25.
    Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983; 249(23): 3189–95PubMedCrossRefGoogle Scholar
  26. 26.
    White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999; 103(6): e73PubMedCrossRefGoogle Scholar
  27. 27.
    Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000; 106(5): 973–6PubMedCrossRefGoogle Scholar
  28. 28.
    Dayan GH, Nguyen VH, Debbag R, et al. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001; 19(30): 4204–13PubMedCrossRefGoogle Scholar
  29. 29.
    Fitzner KA, Shortridge KF, McGhee SM, et al. Cost-effectiveness study on influenza prevention in Hong Kong. Health Policy 2001; 56(3): 215–34PubMedCrossRefGoogle Scholar
  30. 30.
    Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108(2): E24PubMedCrossRefGoogle Scholar
  31. 31.
    Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7(35): 1–170Google Scholar
  32. 32.
    Hall JL, Katz BZ. Cost of influenza hospitalization at a tertiary care children’s hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months. J Pediatr 2005; 147(6): 807–11PubMedCrossRefGoogle Scholar
  33. 33.
    Meltzer MI, Neuzil KM, Griffin MR, et al. An economic analysis of annual influenza vaccination of children. Vaccine 2005; 23(8): 1004–14PubMedCrossRefGoogle Scholar
  34. 34.
    Weycker D, Edelsberg J, Halloran ME, et al. Populationwide benefits of routine vaccination of children against influenza. Vaccine 2005; 23(10): 1284–93PubMedCrossRefGoogle Scholar
  35. 35.
    Esposito S, Marchisio P, Bosis S, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 2006; 24(5): 629–35PubMedCrossRefGoogle Scholar
  36. 36.
    Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 2006; 12(10): 1548–58PubMedCrossRefGoogle Scholar
  37. 37.
    Salo H, Kilpi T, Sintonen H, et al. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006; 24(23): 4934–41PubMedCrossRefGoogle Scholar
  38. 38.
    Skowronski DM, Woolcott JC, Tweed SA, et al. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine 2006; 24(19): 4222–32PubMedCrossRefGoogle Scholar
  39. 39.
    Pisu M, Meltzer MI, Hurwitz ES, et al. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study. Pharmacoeconomics 2005; 23(1): 55–67PubMedCrossRefGoogle Scholar
  40. 40.
    Hibbert CL, Piedra PA, McLaurin KK, et al. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending daycare centres. Vaccine 2007; 25(47): 8010–20PubMedCrossRefGoogle Scholar
  41. 41.
    Marchetti M, Kühnel UM, Colombo GL, et al. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 2007; 3(1): 14–22PubMedCrossRefGoogle Scholar
  42. 42.
    Navas E, Salleras L, Domínguez A, et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3–14 years from the provider and societal perspectives. Vaccine 2007; 25(16): 3233–9PubMedCrossRefGoogle Scholar
  43. 43.
    Luce BR, Nichol KL, Belshe RB, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine 2008; 26(23): 2841–8PubMedCrossRefGoogle Scholar
  44. 44.
    Schmier J, Li S, King Jr JC, et al. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Affairs 2008; 27(2): w96–104PubMedCrossRefGoogle Scholar
  45. 45.
    Salleras L, Navas E, Domínguez A, et al. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3–14 years during the annual health examination in private paediatric offices. Vaccine 2009; 27(25–26): 3454–8PubMedCrossRefGoogle Scholar
  46. 46.
    Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 2: CD004879PubMedGoogle Scholar
  47. 47.
    Newall AT, Kelly H, Harsley S, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009; 27(6): 439–50PubMedCrossRefGoogle Scholar
  48. 48.
    Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001; 17(6): 1282–93PubMedCrossRefGoogle Scholar
  49. 49.
    Navarro-Mari JM, Pérez-Ruiz M, Cantudo-Munoz P, et al. Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol 2005; 58(3): 275–9PubMedCrossRefGoogle Scholar
  50. 50.
    Fujieda M, Maeda A, Kondo K, et al. Influenza vaccine effectiveness and confounding factors among young children. Vaccine 2008; 26(50): 6481–5PubMedCrossRefGoogle Scholar
  51. 51.
    Keren R, Zaoutis TE, Saddlemire S, et al. Direct medical cost of influenza-related hospitalizations in children. Pediatrics 2006; 118(5): e1321–7PubMedCrossRefGoogle Scholar
  52. 52.
    Lambert SB, Allen KM, Carter RC, et al. The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children. Respir Res 2008; 9: 11PubMedCrossRefGoogle Scholar
  53. 53.
    Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26(3): 191–215PubMedCrossRefGoogle Scholar
  54. 54.
    Halloran ME, Longini IM, Cowart DM, et al. Community interventions and the epidemic prevention potential. Vaccine 2002; 20(27–28): 3254–62PubMedGoogle Scholar
  55. 55.
    Basta NE, Chao DL, Halloran ME, et al. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170(6): 679–86PubMedCrossRefGoogle Scholar
  56. 56.
    Vynnycky E, Pitman R, Siddiqui R, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine 2008; 26(41): 5321–30PubMedCrossRefGoogle Scholar
  57. 57.
    Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11(6): 482–7PubMedCrossRefGoogle Scholar
  58. 58.
    Hens N, Goeyvaerts N, Aerts M, et al. Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium. BMC Infectious Diseases 2009; 9: 5PubMedCrossRefGoogle Scholar
  59. 59.
    Goeyvaerts N, Hens N, Ogunjimi B, et al. Estimating infectious disease parameters from data on social contacts and serological status. J Royal Stat Soc C-App 2010; 59(2): 255–77CrossRefGoogle Scholar
  60. 60.
    Ogunjimi B, Hens N, Goeyvaerts N, et al. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. Math Biosci 2009; 218(2): 80–7PubMedCrossRefGoogle Scholar
  61. 61.
    Bilcke J, Beutels P, Brisson M, et al. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011; 31(4): 675–92PubMedCrossRefGoogle Scholar
  62. 62.
    Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011; 29(5): 371–86PubMedCrossRefGoogle Scholar
  63. 63.
    Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25(39–40): 6852–62PubMedCrossRefGoogle Scholar
  64. 64.
    Smith RD, Sach TH. Contingent valuation: what needs to be done? Health Econ Policy Law 2010; 5(1): 91–111PubMedCrossRefGoogle Scholar
  65. 65.
    Polsky D, Willke RJ, Scott K, et al. Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ 2001; 10(1): 39–52CrossRefGoogle Scholar
  66. 66.
    National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008Google Scholar
  67. 67.
    Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Ottawa (ON): CADTH, 2006Google Scholar
  68. 68.
    Knies S, Severens JL, Ament AJHA, et al. The transferability of valuing lost productivity across jurisdictions: differences between national pharmacoeconomic guidelines. Value Health 2010; 13(5): 519–27PubMedCrossRefGoogle Scholar
  69. 69.
    Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd rev. ed. Oxford: Oxford University Press, 2005Google Scholar
  70. 70.
    Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005; 115(5): e600–14PubMedCrossRefGoogle Scholar
  71. 71.
    Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6(3): 253–9PubMedCrossRefGoogle Scholar
  72. 72.
    Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004; 10(4): 5Google Scholar
  73. 73.
    Newall AT, Viboud C, Wood JG. Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiol Infect 2010; 138(6): 836–42PubMedCrossRefGoogle Scholar
  74. 74.
    Influenza vaccines. Wkly Epidemiol Rec 2005; 80(33): 279–87Google Scholar
  75. 75.
    Hoskins TW, Davies JR, Allchin A. Controlled trial of inactivated influenza vaccine containing the A/Hong Kong strain during an outbreak of influenza due to the A/England/42/72 strain. Lancet 1973; 2(7821): 116–20PubMedCrossRefGoogle Scholar
  76. 76.
    Briscoe JH. The protective effect of influenza vaccine in a mixed influenza A and B epidemic in a boys’ boarding school. J R Coll Gen Pract 1977; 27(166): 28–31PubMedGoogle Scholar
  77. 77.
    Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14(4): 339–47PubMedCrossRefGoogle Scholar
  78. 78.
    Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002; 185(2): 147–52PubMedCrossRefGoogle Scholar
  79. 79.
    Newall AT, Wood JG, Oudin N, et al. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerg Infect Dis 2010; 16(2): 224–30PubMedCrossRefGoogle Scholar
  80. 80.
    Baguelin M, Hoek AJV, Jit M, et al. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 2010; 28(12): 2370–84PubMedCrossRefGoogle Scholar
  81. 81.
    Gojovic MZ, Sander B, Fisman D, et al. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009; 181(10): 673–80PubMedGoogle Scholar
  82. 82.
    Lee BY, Brown ST, Korch GW, et al. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 2010; 28(31): 4875–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Anthony T. Newall
    • 1
    Email author
  • Mark Jit
    • 2
  • Philippe Beutels
    • 1
    • 3
  1. 1.School of Public Health and Community MedicineUniversity of New South WalesSydneyAustralia
  2. 2.Modelling and Economics UnitHealth Protection AgencyLondonUK
  3. 3.Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID), Vaccine and Infectious Disease InstituteUniversity of AntwerpAntwerpBelgium

Personalised recommendations